Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 25, 2025
Product Development
Indication selection: Lessons learned from the CRISPR-Cas9 story
Founding CEOs of gene editing companies discuss their pipeline strategies and lessons learned
BioCentury | Feb 18, 2025
Product Development
Remaking Roche
How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Mar 1, 2024
Product Development
Rare disease spotlight: enzyme replacement therapy for the brain
At least seven companies aim to overcome the challenge of delivering an enzyme across the blood-brain barrier to treat MPS IIIA
BioCentury | Sep 18, 2023
Product Development
Data comp: four hypertension candidates advancing in the clinic
Idorsia’s aprocitentan under review, while Mineralys and AZ prepare for Phase III trials and Alnylam runs two more Phase II studies
BioCentury | Jul 24, 2023
Deals
Alnylam continues shift to common diseases, with Roche as hypertension partner
Pharma pays $310M up front to share rights to RNAi therapy; betting on CVOT data, less frequent dosing to outcompete generics
BioCentury | Nov 19, 2018
Preclinical News
RNAi method targets placenta directly to treat preeclampsia
Items per page:
1 - 10 of 76